Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7601)
All Articles published online
|
Publishing Process of This Article
|
Feb 15, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World J Gastrointest Oncol 2016; 8(2): 222-230 [PMID: 26909137 DOI: 10.4251/wjgo.v8.i2.222] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v8/i2/222.htm |
| Number | Citing Articles |
| 1 |
Ramya Thota, Mingli Yang, Lance Pflieger, Michael J. Schell, Malini Rajan, Thomas B. Davis, Heiman Wang, Angela Presson, Warren Jack Pledger, Timothy J. Yeatman. APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes. Cancers 2021; 13(21): 5394 doi: 10.3390/cancers13215394
|
| 2 |
Alessia Bignucolo, Lucia Scarabel, Giuseppe Toffoli, Erika Cecchin, Elena De Mattia. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Expert Review of Clinical Pharmacology 2022; 15(6): 689 doi: 10.1080/17512433.2022.2101447
|
| 3 |
M. C. Merlano, A. Abbona, N. Denaro, O. Garrone. Knowing the tumour microenvironment to optimise immunotherapy. Acta Otorhinolaryngologica Italica 2019; 39(1): 2 doi: 10.14639/0392-100X-2481
|
| 4 |
Federica Pecci, Luca Cantini, Alessandro Bittoni, Edoardo Lenci, Alessio Lupi, Sonia Crocetti, Enrica Giglio, Riccardo Giampieri, Rossana Berardi. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. Current Treatment Options in Oncology 2021; 22(8) doi: 10.1007/s11864-021-00870-z
|
| 5 |
Laura Lattanzio, Nerina Denaro, Daniela Vivenza, Chiara Varamo, Giuliana Strola, Mirella Fortunato, Emmanuel Chamorey, Alberto Comino, Martino Monteverde, Cristiana Lo Nigro, Gerard Milano, Marco Merlano. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy. Cancer Immunology, Immunotherapy 2017; 66(5): 573 doi: 10.1007/s00262-017-1960-8
|
| 6 |
Barbara Seliger. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.00999
|
| 7 |
Robert L. Ferris, Heinz-Josef Lenz, Anna Maria Trotta, Jesús García-Foncillas, Jeltje Schulten, François Audhuy, Marco Merlano, Gerard Milano. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treatment Reviews 2018; 63: 48 doi: 10.1016/j.ctrv.2017.11.008
|
| 8 |
Wenda Ye, Nicole C. Schmitt, Robert L. Ferris, Clint T. Allen. Improving the Therapeutic Ratio in Head and Neck Cancer. 2020; : 107 doi: 10.1016/B978-0-12-817868-3.00006-8
|
| 9 |
Susumu Okano. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development. Auris Nasus Larynx 2024; 51(4): 684 doi: 10.1016/j.anl.2024.05.001
|
| 10 |
Anna-Lena Geißler, Miriam Geißler, Daniel Kottmann, Lisa Lutz, Christiane D. Fichter, Ralph Fritsch, Britta Weddeling, Frank Makowiec, Martin Werner, Silke Lassmann. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. Oncotarget 2017; 8(10): 17164 doi: 10.18632/oncotarget.15211
|
| 11 |
Wang Gang, Jun‐Jie Wang, Rui Guan, Sun Yan, Feng Shi, Jia‐Yan Zhang, Zi‐Meng Li, Jing Gao, Xing‐Li Fu. Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Cancer Medicine 2018; 7(5): 1578 doi: 10.1002/cam4.1386
|
| 12 |
Cristiana Lo Nigro, Vincenzo Ricci, Daniela Vivenza, Cristina Granetto, Teresa Fabozzi, Emanuela Miraglio, Marco C Merlano. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World Journal of Gastroenterology 2016; 22(30): 6944-6954 doi: 10.3748/wjg.v22.i30.6944
|
| 13 |
Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Yan Yang, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Tianshu Liu, Volker Heinemann, Alfredo Falcone, Lin Shen, Joshua Millstein, Heinz-Josef Lenz. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. European Journal of Cancer 2022; 172: 22 doi: 10.1016/j.ejca.2022.05.016
|
| 14 |
Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Jeltje Schulten, Pauline Chomette, Ana Ferreira Castro, Lisa Licitra. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Frontiers in Oncology 2017; 7 doi: 10.3389/fonc.2017.00072
|
| 15 |
Nadia Saoudi González, Javier Ros, Iosune Baraibar, Francesc Salvà, Marta Rodríguez-Castells, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers 2024; 16(2): 412 doi: 10.3390/cancers16020412
|
| 16 |
Kristin C. Hicks, Massimo Fantini, Renee N. Donahue, Angie Schwab, Karin M. Knudson, Sarah R. Tritsch, Caroline Jochems, Paul E. Clavijo, Clint T. Allen, James W. Hodge, Kwong Y. Tsang, Jeffrey Schlom, Sofia R. Gameiro. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. OncoImmunology 2018; 7(11) doi: 10.1080/2162402X.2018.1466018
|
| 17 |
Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Yan Yang, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Tianshu Liu, Volker Heinemann, Alfredo Falcone, Lin Shen, Joshua Millstein, Heinz-Josef Lenz. Genetic Variants Involved in the cGAS-STING Pathway Predict Outcome in Patients with Metastatic Colorectal Cancer: Data from FIRE-3 and TRIBE Trials. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4076696
|
| 18 |
Nico B. Volz, Diana L. Hanna, Sebastian Stintzing, Wu Zhang, Dongyun Yang, Shu Cao, Yan Ning, Satoshi Matsusaka, Yu Sunakawa, Martin D. Berger, Chiara Cremolini, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers 2020; 12(10): 2947 doi: 10.3390/cancers12102947
|
| 19 |
Lorenzo Mortara, Marzia B. Gariboldi, Annalisa Bosi, Marco Bregni, Graziella Pinotti, Luigina Guasti, Alessandro Squizzato, Douglas M. Noonan, Elena Monti, Leonardo Campiotti. Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells. Targeted Oncology 2018; 13(5): 657 doi: 10.1007/s11523-018-0586-x
|
| 20 |
Khurum Khan, Nicola Valeri, Charles Dearman, Sheela Rao, David Watkins, Naureen Starling, Ian Chau, David Cunningham. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology 2019; 143: 153 doi: 10.1016/j.critrevonc.2019.09.001
|
| 21 |
Julian E. Riedesser, Matthias P. Ebert, Johannes Betge. Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359211072703
|
| 22 |
A. Borrero-Palacios, A. Cebrián, M. T. Gómez del Pulgar, R. García-Carbonero, P. Garcia-Alfonso, E. Aranda, E. Elez, R. López-López, A. Cervantes, M. Valladares, C. Nadal, J. M. Viéitez, C. Guillén-Ponce, J. Rodríguez, I. Hernández, J. L. García, R. Vega-Bravo, A. Puime-Otin, J. Martínez-Useros, L. Del Puerto-Nevado, R. Rincón, M. Rodríguez-Remírez, F. Rojo, J. García-Foncillas. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-39291-2
|
| 23 |
Tao Hu, Zhen Li, Chun-Ying Gao, Chi Hin Cho. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World Journal of Gastroenterology 2016; 22(30): 6876-6889 doi: 10.3748/wjg.v22.i30.6876
|
| 24 |
Lucia Scarabel, Alessia Bignucolo, Giuseppe Toffoli, Erika Cecchin, Elena De Mattia. Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC. Pharmaceutics 2022; 14(11): 2468 doi: 10.3390/pharmaceutics14112468
|
| 25 |
Barbara Manzanares-Martin, Arancha Cebrián Aranda, Laura del Puerto-Nevado, Rafael González, Sonia Solanes, Maria Auxiliadora Gómez-España, Jesús García-Foncillas, Enrique Aranda. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. Journal for ImmunoTherapy of Cancer 2021; 9(4): e001705 doi: 10.1136/jitc-2020-001705
|